Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library

Vancouver, British Columbia – July 6, 2017 – Sirona Biochem Corp. (TSX-V: SBM) (FRANKFURT: ZSB) (Xetra: ZSB) (the “Company”) announced positive preclinical efficacy data for its library of skin lightening compounds.

The study was conducted at Bioalternatives in France, a contract research organization specializing in cellular and molecular pharmacology. The study looked at each of six compounds’ ability to inhibit melanin synthesis induced by L-tyrosine for 10 days in normal human epidermal melanocytes. Results showed a significant decrease in melanin synthesis with a similar efficacy across the library. Inhibiting melanin production is the principal mechanism of action for the majority of skin lighteners in clinical use.

“In December 2016, we announced the completion of our skin lightening library, with plans to begin testing in 2017”, said Dr. Howard Verrico, CEO. “The positive efficacy of these compounds adds value to a licensing transaction as it increases the opportunity for commercialization in various markets and therapeutic areas. Moreover, this data will be used to support and strengthen our IP in this area.”

Sirona has shared these results with the multinational companies currently working towards a license to commercialize TFC-1067.

 

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, please contact:

Christopher Hopton, CFO
Sirona Biochem Corp.
Phone:  1.604.282.6064
Email: chopton@sironabiochem.com

 

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.